

Tilman Brummer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9282383/publications.pdf>

Version: 2024-02-01

108
papers

5,897
citations

81434

41
h-index

90395

73
g-index

114
all docs

114
docs citations

114
times ranked

11571
citing authors

#	ARTICLE	IF	CITATIONS
1	Spontaneous activity of the mitochondrial apoptosis pathway drives chromosomal defects, the appearance of micronuclei and cancer metastasis through the Caspase-Activated DNase. <i>Cell Death and Disease</i> , 2022, 13, 315.	2.7	14
2	Gab2 deficiency prevents FIt3-ITD driven acute myeloid leukemia in vivo. <i>Leukemia</i> , 2022, 36, 970-982.	3.3	4
3	LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma. <i>Neuro-Oncology</i> , 2022, 24, i91-i91.	0.6	0
4	LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma. <i>Neuro-Oncology</i> , 2022, 24, i94-i94.	0.6	0
5	Functional coupling of presequence processing and degradation in human mitochondria. <i>FEBS Journal</i> , 2021, 288, 600-613.	2.2	18
6	Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. <i>Cancers</i> , 2021, 13, 1151.	1.7	27
7	Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition. <i>Cancers</i> , 2021, 13, 1852.	1.7	3
8	Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field. <i>Lung Cancer</i> , 2021, 154, 131-141.	0.9	8
9	Oncogenic <i>KrasG12D</i> Activation in the Nonhematopoietic Bone Marrow Microenvironment Causes Myelodysplastic Syndrome in Mice. <i>Molecular Cancer Research</i> , 2021, 19, 1596-1608.	1.5	5
10	LGG-04. MULTIOMIC ANALYSIS OF MAPK PATHWAY ACTIVITY IN PEDIATRIC PILOCYTIC ASTROCYTOMA. <i>Neuro-Oncology</i> , 2021, 23, i31-i32.	0.6	0
11	Global kinome profiling reveals DYRK1A as critical activator of the human mitochondrial import machinery. <i>Nature Communications</i> , 2021, 12, 4284.	5.8	15
12	Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts. <i>Cell Communication and Signaling</i> , 2021, 19, 123.	2.7	3
13	Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. <i>Oncogene</i> , 2020, 39, 814-832.	2.6	19
14	Cathepsin D deficiency in mammary epithelium transiently stalls breast cancer by interference with mTORC1 signaling. <i>Nature Communications</i> , 2020, 11, 5133.	5.8	37
15	BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation. <i>Oncogene</i> , 2020, 39, 6053-6070.	2.6	19
16	Immune modulatory effects of oncogenic KRAS in cancer. <i>Nature Communications</i> , 2020, 11, 5439.	5.8	188
17	Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	70
18	Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans. <i>Blood</i> , 2020, 136, 1442-1455.	0.6	60

#	ARTICLE	IF	CITATIONS
19	RAF kinase dimerization: implications for drug discovery and clinical outcomes. <i>Oncogene</i> , 2020, 39, 4155-4169.	2.6	44
20	Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation. <i>Nature Communications</i> , 2020, 11, 1659.	5.8	92
21	A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in <i>BRAF</i> -Driven Pediatric Low-Grade Glioma Cells. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1736-1750.	1.9	13
22	LGG-17. SYNERGISTIC ACTIVITY OF MAPK INHIBITOR CLASSES REVEALED BY A NOVEL CELL-BASED MAPK ACTIVITY PEDIATRIC LOW-GRADE GLIOMA ASSAY. <i>Neuro-Oncology</i> , 2020, 22, iii369-iii369.	0.6	0
23	B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model. <i>Oncogene</i> , 2019, 38, 1324-1339.	2.6	10
24	Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3886-3897.	2.9	23
25	Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia. <i>HemaSphere</i> , 2019, 3, e184.	1.2	4
26	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. <i>International Journal of Cancer</i> , 2019, 145, 649-661.	2.3	85
27	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. <i>Clinical Cancer Research</i> , 2019, 25, 1851-1866.	3.2	55
28	Abstract LB-B08: Identification and characterization of an unusual BRAF fusion oncoprotein with retained autoinhibitory domains. , 2019, , .		0
29	Oncogenic JAK2 ^{V617F} causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	166
30	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	15.2	216
31	CDK9-mediated phosphorylation controls the interaction of TIP60 with the transcriptional machinery. <i>EMBO Reports</i> , 2018, 19, 244-256.	2.0	16
32	BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. <i>Oncogene</i> , 2018, 37, 1576-1593.	2.6	37
33	Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-16.	1.5	41
34	LGG-11. REGULATION OF ONCOGENE-INDUCED SENESCENCE IN PILOCYTIC ASTROCYTOMA. <i>Neuro-Oncology</i> , 2018, 20, i106-i106.	0.6	0
35	Targeting oncogenic Ras by the <i>Clostridium perfringens</i> toxin TpeL. <i>Oncotarget</i> , 2018, 9, 16489-16500.	0.8	9
36	Discrete cytosolic macromolecular <i>BRAF</i> complexes exhibit distinct activities and composition. <i>EMBO Journal</i> , 2017, 36, 646-663.	3.5	52

#	ARTICLE	IF	CITATIONS
37	MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation. <i>Leukemia</i> , 2017, 31, 2732-2741.	3.3	88
38	The Atypical Kinase R1OK1 Promotes Tumor Growth and Invasive Behavior. <i>EBioMedicine</i> , 2017, 20, 79-97.	2.7	55
39	Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin- β 1 expression. <i>Oncotarget</i> , 2017, 8, 42901-42916.	0.8	60
40	Specific role of RhoC in tumor invasion and metastasis. <i>Oncotarget</i> , 2017, 8, 87364-87378.	0.8	23
41	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. <i>Oncotarget</i> , 2017, 8, 11460-11479.	0.8	43
42	Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles. <i>Oncotarget</i> , 2016, 7, 26628-26652.	0.8	25
43	LG-27DKFZ-BT66 - A NOVEL PILOCYTIC ASTROCYTOMA MODEL FOR PRECLINICAL DRUG TESTING. <i>Neuro-Oncology</i> , 2016, 18, iii84.3-iii84.	0.6	0
44	B-Raf activation loop phosphorylation revisited. <i>Cell Cycle</i> , 2016, 15, 1171-1173.	1.3	22
45	Small Molecule Stabilization of the β 3/Gab2 Protein-Protein Interaction (PPI) Interface. <i>ChemMedChem</i> , 2016, 11, 911-918.	1.6	54
46	MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib. <i>Breast Cancer Research</i> , 2016, 18, 125.	2.2	60
47	Activation loop phosphorylation regulates B-Raf <i>in vivo</i> and transformation by B-Raf mutants. <i>EMBO Journal</i> , 2016, 35, 143-161.	3.5	29
48	Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model. <i>Leukemia</i> , 2016, 30, 1942-1945.	3.3	10
49	BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. <i>Blood</i> , 2016, 127, 2847-2855.	0.6	100
50	Quantitative Proteomics Analysis of Leukemia Cells. <i>Methods in Molecular Biology</i> , 2016, 1465, 139-148.	0.4	1
51	Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. <i>Nature Medicine</i> , 2016, 22, 1314-1320.	15.2	183
52	UV-B-induced cutaneous inflammation and prospects for antioxidant treatment in Kindler syndrome. <i>Human Molecular Genetics</i> , 2016, 25, dww350.	1.4	13
53	Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. <i>Cell Communication and Signaling</i> , 2016, 14, 6.	2.7	15
54	ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. <i>Nature Communications</i> , 2016, 7, 10498.	5.8	273

#	ARTICLE	IF	CITATIONS
55	Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis. <i>Oncotarget</i> , 2016, 7, 7960-7969.	0.8	18
56	Effect of biglycan on melanoma invasiveness via increased tissue stiffness and integrin- β 1 expression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11526-11526.	0.8	0
57	Implementation of a Molecular Tumor Board in Clinical Decision Making at the Medical Center University of Freiburg. <i>Blood</i> , 2016, 128, 3579-3579.	0.6	0
58	Exometabolom analysis of breast cancer cell lines: Metabolic signature. <i>Scientific Reports</i> , 2015, 5, 13374.	1.6	24
59	A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells. <i>International Journal of Cancer</i> , 2015, 137, 2566-2577.	2.3	152
60	Global gene expression profiling analysis reveals reduction of stemness after B-RAF inhibition in colorectal cancer cell lines. <i>Genomics Data</i> , 2015, 4, 158-161.	1.3	2
61	BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?. <i>Molecular and Cellular Oncology</i> , 2015, 2, e1002709.	0.3	5
62	Metadherin exon 11 skipping variant enhances metastatic spread of ovarian cancer. <i>International Journal of Cancer</i> , 2015, 136, 2328-2340.	2.3	13
63	Kidins220/ARMS binds to the B cell antigen receptor and regulates B cell development and activation. <i>Journal of Experimental Medicine</i> , 2015, 212, 1693-1708.	4.2	18
64	Differential tyrosine phosphorylation controls the function of CNK1 as a molecular switch in signal transduction. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 2847-2855.	1.9	7
65	B-Raf Inhibitors Induce Epithelial Differentiation in BRAF-Mutant Colorectal Cancer Cells. <i>Cancer Research</i> , 2015, 75, 216-229.	0.4	43
66	The EMT-activator ZEB1 induces bone metastasis associated genes including BMP-inhibitors. <i>Oncotarget</i> , 2015, 6, 14399-14412.	0.8	46
67	Cooperative Activity of BRAF F595L and Mutant HRAS in Histiocytic Sarcoma Provides New Insights into Oncogenic BRAF Signaling. <i>Blood</i> , 2015, 126, 1631-1631.	0.6	2
68	BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2014, 124, 5074-5084.	3.9	56
69	EGFR-Targeted TRAIL and a Smac Mimetic Synergize to Overcome Apoptosis Resistance in KRAS Mutant Colorectal Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e107165.	1.1	27
70	Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice. <i>Blood Cancer Journal</i> , 2014, 4, e240-e240.	2.8	10
71	Expression pattern and first functional characterization of riok-1 in <i>Caenorhabditis elegans</i> . <i>Gene Expression Patterns</i> , 2014, 15, 124-134.	0.3	13
72	Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells. <i>Cell Communication and Signaling</i> , 2013, 11, 30.	2.7	15

#	ARTICLE	IF	CITATIONS
73	A generic strategy for pharmacological caging of growth factors for tissue engineering. <i>Chemical Communications</i> , 2013, 49, 5927.	2.2	8
74	Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 122, 1621-1633.	0.6	57
75	Functional characterization of cancer-associated Gab1 mutations. <i>Oncogene</i> , 2013, 32, 2696-2702.	2.6	33
76	Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. <i>Leukemia</i> , 2013, 27, 118-129.	3.3	48
77	Kidins220/ARMS Associates with B-Raf and the TCR, Promoting Sustained Erk Signaling in T Cells. <i>Journal of Immunology</i> , 2013, 190, 1927-1935.	0.4	32
78	PKD controls mitotic Golgi complex fragmentation through a Rafâ€“MEK1 pathway. <i>Molecular Biology of the Cell</i> , 2013, 24, 222-233.	0.9	23
79	ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer. <i>PLoS Biology</i> , 2012, 10, e1001461.	2.6	74
80	Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. <i>EMBO Journal</i> , 2012, 31, 2629-2647.	3.5	110
81	The RhoGAP protein Deleted in Liver Cancer 3 (DLC3) is essential for adherens junctions integrity. <i>Oncogenesis</i> , 2012, 1, e13-e13.	2.1	34
82	The Versatile Role of Gab1 in the Circulatory System. <i>Circulation Journal</i> , 2012, 76, 1838-1839.	0.7	0
83	Aberrant B-Raf Signaling in Human Cancer â€™ 10 Years from Bench to Bedside. <i>Critical Reviews in Oncogenesis</i> , 2012, 17, 97-121.	0.2	56
84	The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia. <i>Human Pathology</i> , 2011, 42, 719-726.	1.1	22
85	Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. <i>Molecular Systems Biology</i> , 2011, 7, 489.	3.2	172
86	Oncogenic FAM131Bâ€“BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2011, 121, 763-774.	3.9	211
87	A novel MCF-10A line allowing conditional oncogene expression in 3D culture. <i>Cell Communication and Signaling</i> , 2011, 9, 17.	2.7	34
88	Functional characterization of a <i>BRAF</i> insertion mutant associated with pilocytic astrocytoma. <i>International Journal of Cancer</i> , 2011, 129, 2297-2303.	2.3	75
89	Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation. <i>Molecular Biology of the Cell</i> , 2011, 22, 105-116.	0.9	22
90	Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development. <i>International Journal of Cancer</i> , 2010, 127, 1486-1492.	2.3	31

#	ARTICLE	IF	CITATIONS
91	Docking proteins. FEBS Journal, 2010, 277, 4356-4369.	2.2	44
92	DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 1003-1012.	1.9	25
93	Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochemical Journal, 2009, 418, 475-489.	1.7	647
94	How to Grb2 a Gab. Structure, 2009, 17, 779-781.	1.6	11
95	Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Communication and Signaling, 2009, 7, 22.	2.7	151
96	Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein. EMBO Journal, 2008, 27, 2305-2316.	3.5	55
97	Gab2 and Src co-operate in human mammary epithelial cells to promote growth factor independence and disruption of acinar morphogenesis. Oncogene, 2008, 27, 2693-2704.	2.6	42
98	Signalling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative. , 2008, , 224-244.		1
99	Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nature Immunology, 2006, 7, 274-283.	7.0	228
100	Functional analysis of the regulatory requirements of B-Raf and the B-RafV600E oncoprotein. Oncogene, 2006, 25, 6262-6276.	2.6	70
101	Increased Proliferation and Altered Growth Factor Dependence of Human Mammary Epithelial Cells Overexpressing the Gab2 Docking Protein. Journal of Biological Chemistry, 2006, 281, 626-637.	1.6	108
102	Adenosine and cAMP are potent inhibitors of the NF- κ B pathway downstream of immunoreceptors. European Journal of Immunology, 2005, 35, 31-41.	1.6	169
103	B-Cell Signal Transduction. , 2004, 271, 189-212.		21
104	Feedback regulation of lymphocyte signalling. Nature Reviews Immunology, 2004, 4, 269-278.	10.6	73
105	A revised and complete map of the chicken c-mil/raf-1 locus. Oncogene, 2004, 23, 3128-3131.	2.6	1
106	Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene, 2003, 22, 8823-8834.	2.6	103
107	The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion. Nature Immunology, 2003, 4, 38-43.	7.0	167
108	Inducible gene deletion reveals different roles for B-Raf and Raf-1 in B-cell antigen receptor signalling. EMBO Journal, 2002, 21, 5611-5622.	3.5	73